Eli Lilly therapy solanezumab did not gradual illness
Eli Lilly on Wednesday stated it’ll halt improvement of its Alzheimer’s therapy candidate solanezumab after the antibody did not gradual illness development. Solanezumab’s failure is a blow to efforts to…